Comparison of disease‐specific quality of life in prostate cancer patients treated with low‐dose‐rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil

Objectives To compare the effects of naftopidil and silodosin administration on the quality of life of patients with prostate cancer who underwent low‐dose‐rate brachytherapy. Methods In total, 141 men diagnosed with localized prostate cancer who were treated with low‐dose‐rate brachytherapy were enrolled. Patients were randomized (1:1) to the naftopidil (75 mg/day, n = 63) or silodosin group (8 mg/day, n = 64). Naftopidil and silodosin were administered 1 day after low‐dose‐rate brachytherapy, and were continued for at least 3 months. Using the University of California at Los Angeles Prostate Cancer Index and Sexual Health Inventory for Men scores, the mean changes and rates of deterioration from baseline were compared. The deterioration rates in the quality of life of patients at 1 and 3 months after low‐dose‐rate brachytherapy were evaluated based on the minimal important difference. Results The rates of deterioration from baseline to 1 and 3 months after low‐dose‐rate brachytherapy were not significantly different between the two groups in terms of urinary function, urinary bother, bowel bother, sexual function or Sexual Health Inventory for Men scores. In contrast, there were significant differences in bowel function (naftopidil 1 month, 52%; 3 months, 52%; silodosin 1 month, 28%; 3 months, 34%; 1 month, P